Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) will report its third quarter fiscal year 2026 financial results and host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. The call will be led by CEO Bob Jahr and EVP/CFO Lawrence A. Kenyon. Domestic participants can dial 877-407-8291, international participants can dial +1 201-689-8345, referencing the Outlook Therapeutics conference call. A live webcast and 90-day archive will be available on the Events page in the Investor section of the company’s website, outlooktherapeutics.com.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 24 | FDA approval | Positive | +6.4% | FDA approved LYTENAVA for wet age-related macular degeneration treatment. |
| Jun 16 | BLA acceptance | Positive | +35.3% | FDA accepted the resubmitted biologics license application under Class 1 review. |
| Jun 01 | BLA resubmission | Positive | +15.5% | Company resubmitted its biologics license application to the FDA. |
| May 28 | Registered offering | Negative | -1.4% | Company priced a $5.0 million registered direct offering. |
| May 26 | FDA appeal win | Positive | +29.1% | FDA granted the company's formal dispute resolution appeal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
OTLK's five selected recent news events all showed price reactions aligned with the reported catalyst sentiment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET.
The call will be hosted by members of Outlook Therapeutics’ leadership team, Bob Jahr, Chief Executive Officer, and Lawrence A. Kenyon, Executive Vice President and Chief Financial Officer. Interested participants and investors may access the conference call by dialing 877-407-8291 (domestic) or +1 201-689-8345 (international) and referencing the Outlook Therapeutics conference call. The webcast will be accessible on the Events page of the Investor section of the Outlook Therapeutics website, outlooktherapeutics.com. It will also accessible here and will be archived for 90 days.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
